Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis
Highlight
1. Intravenous tenecteplase showed a neutral effect on 90-day functional outcomes in minor ischemic stroke patients categorized as having disabling deficits based on NIHSS.
2. Patients with disabling symptoms had higher NIHSS scores and presented later with longer onset-to-treatment times.
3. Standard NIHSS-based definitions of disabling stroke did not modify treatment response to tenecteplase.
4. Findings suggest reevaluating intravenous thrombolysis criteria for minor disabling strokes.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.